2 terminated, 1 active not recruiting. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow azeliragon: new trials by email Literature Review of azeliragon trials Research Report on azeliragon
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia Azeliragon, Placebo - COVID-19 | Phase 2 / Phase 3 | Active not recruiting | The University of Texas Medical Branch, Galveston | 144 | 2023-05-04 | 2025-03-03 |
| 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension) Azeliragon 5mg - Alzheimer's Disease | Phase 3 | Terminated | vTv Therapeutics | 297 | 2016-12-01 | 2021-06-01 |
| Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Azeliragon, Placebo - Alzheimer's Disease | Phase 3 | Terminated | vTv Therapeutics | 880 | 2015-04-01 | 2021-05-07 |
Alzheimer Disease (2) · Acute Kidney Injury (1) · COVID-19 (1)
vTv Therapeutics (2) · The University of Texas Medical Branch, Galveston (1)
United States (3) · Canada (2) · Australia (1) · Ireland (1) · New Zealand (1) · South Africa (1) · United Kingdom (1)
Aaron H Burstein, PharmD (1) · Ann Gooch, Ph.D. (1) · Lucas S. Blanton, MD (1)